Saul Genuth

Saul Genuth

Auto-generated profile, based on publicly available information

Saul Genuth

Division of Clinical and Molecular Endocrinology, Department of Medicine, Case Western Reserve University, Cleveland, Ohio 44106-4951, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2003 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
SGSaul Genuth
Saul Genuth
Editor’s comment: Because of the controversial nature of the new lowered criterion for IFG, I offered the Chairman of the Expert Committee an opportunity to respond to my commentary on the subject. I would only point out that Dr. Genuth’s reference 8 shows an association between glycemia and cardiovascular disease (as have many other reports), but to date, five prospective studies, analyzed either singly or as a metanalysis, have been unable to demonstrate a beneficial effect of lowering glycemia on cardiovascular disease outcomes.

1 November 2005 in Diabetes
Verified
Journal Article
Closed access
PDF file
SGSaul Genuth
Saul Genuth
WSWanjie Sun
Wanjie Sun
PCPatricia Cleary
Patricia Cleary
DSDavid R. Sell
David R. Sell
WDWilliam Dahms
William Dahms
FGfor the DCCT Skin Collagen Ancillary Study Group
for the DCCT Skin Collagen Ancillary Study Group
Several mechanistic pathways linking hyperglycemia to diabetes complications, including glycation of proteins and formation of advanced glycation end products (AGEs), have been proposed. We investigated the hypothesis that skin collagen glycation and AGEs predict the risk of progression of microvascular disease. We measured glycation products in the skin collagen of 211 Diabetes Control and Complications Trial (DCCT) volunteers in 1992 who continued to be followed in the Epidemiology of Diabetes Interventions and Complications study for 10 years. We determined whether the earlier measurements of glycated collagen and AGE levels correlated with the risk of progression of retinopathy and nephropathy from the end of the DCCT to 10 years later. In multivariate analyses, the combination of furosine (glycated collagen) and carboxymethyllysine (CML) predicted the progression of retinopathy (χ2 = 59.4, P < 0.0001) and nephropathy (χ2 = 18.2, P = 0.0001), even after adjustment for mean HbA1c (A1C) (χ2 = 32.7, P < 0.0001 for retinopathy) and (χ2 = 12.8, P = 0.0016 for nephropathy). The predictive effect of A1C vanished after adjustment for furosine and CML (χ2 = 0.0002, P = 0.987 for retinopathy and χ2 = 0.0002, P = 0.964 for nephropathy). Furosine explained more of the variation in the 10-year progression of retinopathy and nephropathy than did CML. These results strengthen the role of glycation of proteins and AGE formation in the pathogenesis of retinopathy and nephropathy. Glycation and subsequent AGE formation may explain the risk of these complications associated with prior A1C and provide a rational basis for the phenomenon of “metabolic memory” in the pathogenesis of these diabetes complications.

1 June 2008 in Diabetes Care
Verified
Journal Article
Open access
PDF file
SGSaul Genuth
Saul Genuth
RKRichard Kahn
Richard Kahn

1 January 2009 in US Endocrinology
Verified
Journal Article
Closed access
SGSaul M Genuth
Saul M Genuth
Recognizing the great need to finally resolve the issue of whether lowering blood pressure with intensive treatment will decrease cardiovascular disease (CVD) events in type 2 diabetes, three randomized clinical trials were recently completed. ACCORD, VADT, and ADVANCE all found no significant benefit on primary CVD outcomes and ACCORD reported a 20% increase in total and CVD mortality with intensive treatment. A post-trial observational study by the UKPDS finally noted a decrease of 15% in myocardial infarction and 13% decrease in total mortality over a follow-up of 25 years from the diagnosis of diabetes. The BARI 2D trial found no significant overall advantage of insulin-sensitizing over insulin-providing drugs in these outcomes, although insulin-sensitizing augmented the benefit of coronary bypass surgery over medical therapy. Lowering blood pressure, low-density lipoprotein cholesterol, triglycerides, excessive body fat, and tobacco intake and raising high-density lipoprotein cholesterol may simply overwhelm the small additional benefit gained from reducing glycemia. Metformin has the largest body of evidence supporting its use for decreasing CVD events while reducing glycemia, but uncertainty still surrounds thiazolidinediones.